TFBS Bioscience Enters Strategic Partnership with Australia's QIMR Berghofer

TFBS Bioscience (Headquarters: New Taipei City, Taiwan; hereinafter TFBS) and QIMR Berghofer Medical Research Institute (Headquarters: Queensland, Australia; hereinafter QIMR Berghofer) have signed a Memorandum of Understanding (MOU) for a strategic partnership in the field of cell and gene therapy. Through this partnership, both organizations will integrate their expertise and resources to build a global development framework that accelerates the development of innovative therapies and promotes their expansion into international markets.

Based in Brisbane, Australia, QIMR Berghofer is one of the world's leading comprehensive research institutes driving translational medical research. Its state-of-the-art facility, 'Q-Gen Cell Therapeutics,' has been at the forefront of GMP manufacturing for cell therapy for over 25 years. QIMR Berghofer focuses on rapidly translating innovative therapies from basic research and preclinical development to early-stage clinical applications.

TFBS Bioscience is a specialist in viral vector manufacturing, providing Contract Development and Manufacturing Organization (CDMO) services primarily in the fields of regenerative medicine and cell and gene therapy. While handling everything from viral vector R&D to GMP manufacturing, the company also leverages its advanced analytical technology to provide comprehensive Contract Research Organization (CRO) services for vaccines and biopharmaceuticals in general.

Through this strategic partnership, the two companies will build an integrated service framework for cell and gene therapy clinical trials. By connecting Australia's favorable environment for rapid clinical trial initiation and QIMR Berghofer's clinical and cell manufacturing infrastructure with TFBS Bioscience's viral vector manufacturing and comprehensive CRO services in Taiwan, a robust development and manufacturing supply chain will be established. This will enable the shortest possible timeline from basic research to the start of local clinical trials. The partnership will strongly support the overseas expansion of companies in Asia, including Japan, Taiwan, and South Korea, and accelerate the clinical development of next-generation medicine. The two organizations will also work together to establish this platform in the global market through joint promotions at international conferences.

QIMR Berghofer is a world-leading clinical medical research institute dedicated to delivering excellent scientific outcomes and driving innovation in human health. Established in 1945, the institute has approximately 1,000 scientists, clinicians, support staff, and students, working in four major research areas: cancer research, infectious diseases and inflammation, public health, and brain and mental health.

TFBS Bioscience Inc. (TFBS) was established in 2016 as the first Contract Research Organization (CRO) in Taiwan to provide biological testing, spinning off from the Development Center for Biotechnology (DCB), a government-affiliated research institute in Taiwan. The company possesses Taiwan's first GMP/GCTP manufacturing facility for viral products and provides comprehensive CDMO services from R&D to commercial manufacturing.